title: Anti-CD24 nano-targeted delivery of docetaxel for the treatment of prostate cancer.
abstract: Nanoparticle (NP)-mediated, noninvasively targeted and image-guided therapies have potential to improve efficacy and safety of cancer therapeutics. We report synthesis and use of poly(lactide-co-glycolide)-polyethylene glycol (PLGA-PEG) NPs for targeted delivery of docetaxel. We synthesized docetaxel encapsulated NPs conjugated to anti-CD24 (for targeting) and/or an optical probe (for tracking) and evaluated efficacy in a prostate cancer mouse model. We observed preferential accumulation of anti-CD24 conjugated NPs (encapsulating docetaxel) compared to the non-conjugated NPs 24 hours after a single injection into luciferase-expressing PC3M prostate cancer tumor. In the same mouse model, we found significant (P<0.01) accumulation of docetaxel (~10-fold higher) in tumor after treatment with PLGA-PEG NPs encapsulating docetaxel and conjugated to anti-CD24 compared to non-conjugated NPs. Enhanced accumulation was associated with reduced tumor mass and tumor viability. These data support the potential impact of nano-targeted delivery of chemotherapy in enhancing the differential tumor delivery and anticancer efficacy in prostate cancer.
authors: The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA.
authors: Dhruba J
authors: DJ
authors: Bharali
authors: The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA.
authors: Thangirala
authors: T
authors: Sudha
authors: The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA.
authors: Huadong
authors: H
authors: Cui
authors: Division of Urology, Albany Medical College, Albany, NY, USA.
authors: Badar M
authors: BM
authors: Mian
authors: The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA. Electronic address: shaker.mousa@acphs.edu.
authors: Shaker A
authors: SA
authors: Mousa
mesh_terms: D000818:Animals; D051927:CD24 Antigen / Q000737:chemistry*; D000077143:Docetaxel; D016503:Drug Delivery Systems; D019344:Lactic Acid / Q000737:chemistry; D008297:Male; D051379:Mice; D008819:Mice, Nude; D053758:Nanoparticles / Q000737:chemistry*; D011100:Polyglycolic Acid / Q000737:chemistry; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D051927:CD24 Antigen; D043823:Taxoids; D000077143:Docetaxel; D011100:Polyglycolic Acid; D019344:Lactic Acid
keywords: Anti-CD24; Docetaxel; PLGA nanoparticle; Prostate cancer; Targeted therapy